Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Wang, Shi-Jie; Wang, Yiting; Yu, Jiangtao; Wu, Huaxing; Zhou, Yanming

doi:10.3390/cancers14225525

Cited by 14 publications

(11 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A meta‐analysis has revealed that LENV has superior antitumor response and survival advantages than sorafenib as a first‐line therapy for advanced/unresectable HCC patients. In addition, LENV showcases competitive therapeutic efficacy with similar incidences of AEs 25 …”

Section: Discussionmentioning

confidence: 99%

“…In addition, LENV showcases competitive therapeutic efficacy with similar incidences of AEs. 25 In 2020, a new combination approach of ATE plus BEV was shown to be more beneficial than other first-line drugs due to their favorable safety profiles in advanced HCC patients. 26 ATE/BEV is associated with better PFS, OS, response rate, and preservation of quality of life than sorafenib (IMbrave150).…”

Section: Sensitivity Analysismentioning

confidence: 99%

See 1 more Smart Citation

Atezolizumab Plus Bevacizumab Versus Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis

Lu,

Lin,

Teng

et al. 2024

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is often diagnosed in advanced stages. Following sorafenib, lenvatinib (LENV) has been approved as a first‐line treatment option for unresectable HCC. In the past few years, at least 9 large‐scale cohort studies have examined the efficacy and safety of LENV compared to atezolizumab plus bevacizumab (ATE/BEV) in unresectable HCC, but there is currently no direct meta‐analysis conducted for a comprehensive consolidation. To provide the most updated meta‐analysis of the clinical efficacy and safety of ATE/BEV versus LENV for patients with unresectable HCC. Our studies comparing the efficacy and safety of ATE/BEV and LENV in unresectable HCC were systematically searched in PubMed, Embase, and Web of Science from inception to February 2023. Outcomes measured were overall survival (OS), progression‐free survival (PFS), mortality, complete response (CR), partial response (PR), objective response rate (ORR), disease control rate (DCR), progressive disease (PD), stable disease (SD), and adverse events (AEs). Seven eligible studies involving 4428 patients (1569 in the ATE/BEV group and 2859 in the LENV group) were included in the narrative synthesis. All baseline characteristics were similar between the 2 groups except for Child‐Pugh class B. Ultimately, our meta‐analysis showed that the LENV group had longer OS and PFS than the ATE/BEV group. Moreover, patients on LENV were more likely to achieve SD, whereas those on ATE/BEV were more likely to achieve PR.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Sensitivity Analysismentioning

confidence: 99%

Atezolizumab Plus Bevacizumab Versus Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis

Lu,

Lin,

Teng

et al. 2024

The Journal of Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…These adverse events may be due to lenvatinib as hypertension, diarrhea and gingival bleeding have been reported as common adverse events in unresectable HCC patients treated with lenvatinib. 26 , 27 A recent meta-analysis showed that lenvatinib-induced hypertension may be associated with better prognosis. 28 Lenvatinib-induced adverse events could be managed through regular monitoring, preventive measures and symptomatic management.…”

Section: Discussionmentioning

confidence: 99%

Impact of combining Lenvatinib with Transarterial chemoembolization for unresectable hepatocellular carcinoma

Long,

Liu,

Yang

et al. 2023

Pak J Med Sci

View full text Add to dashboard Cite

Objectives: To investigate the impact of combining lenvatinib with transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC). Methods: This was a retrospective observational study which reviewed the medical records of 103 unresectable HCC patients from January 2017 to June 2020 in The First Affiliated Hospital of Soochow University. It included 46 patients who received TACE plus lenvatinib and 57 patients who received TACE alone. The levels of serum indicators, clinical effect, adverse events, overall survival (OS), and progression-free survival (PFS) were compared between the two groups. Results: AFP and VEGF levels in the TACE+lenvatinib group post-treatment were significantly lower than the TACE group (P<0.05). The clinical efficacy in the TACE+lenvatinib group (69.57%) was higher than that in the TACE group (40.35%) post-treatment (P<0.05). There were significant differences in hypertension, diarrhea, and bleeding (gingiva) between the two groups (P<0.05). There were no significant differences in one or two year PFS rate or one year OS between groups (P>0.05), while the two years survival rate in the TACE+lenvatinib group was significantly higher than that in the TACE group (P<0.05). Conclusions: TACE combined with lenvatinib have a high clinical effective rate, with reduced AFP and VEGF levels, higher two year survival rate, and acceptable incidence of adverse events. doi: https://doi.org/10.12669/pjms.39.6.7944 How to cite this: Long J, Liu L, Yang X, Lu X, Qin L. Impact of combining Lenvatinib with Transarterial chemoembolization for unresectable hepatocellular carcinoma. Pak J Med Sci. 2023;39(6):---------. doi: https://doi.org/10.12669/pjms.39.6.7944 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

“…Most frequent adverse events in the different studies with lenvatinib and pembrolizumab 4,6,17,18,19 Lenvatinib in TC17…”

Section: Tablementioning

confidence: 99%

Managing the Adverse Events Associated with Pembrolizumab and Lenvatinib Therapy in Endometrial Cancer

Zribi,

Al Riyami,

Al Zahibi

et al. 2024

Sultan Qaboos Univ Med J

View full text Add to dashboard Cite

Endometrial cancer (EC) is the most common gynecological cancer. The combination of lenvatinib plus pembrolizumab has exhibited efficacy as the second line treatment for advanced EC, with a significant benefit in terms of progression free survival (PFS) and overall survival (OS), but the adverse effects (AE) profile is complex. AEs associated with the treatment may represent a limitation to this combination. Here, we report the case of a 38-year-old lady diagnosed with stage IV EC elsewhere, whose disease progressed after the first line of treatment, and was referred to our center in 2021. We treated her with the combination of lenvatinib and pembrolizumab. During the course of the treatment. she developed hand- foot syndrome (HFS) grade III, and hypothyroidism grade II. The AEs were managed with supportive medications, dose interruptions, dose reductions, and multidisciplinary care, which allowed us to continue the treatment. The patient achieved a good partial response, and an ongoing PFS of more than 12 months. Keywords: cancer, endometrial, lenvatinib, pembrolizumab, adverse drug events, hand foot syndrome, hypothyroidism, Oman.

show abstract

Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Cited by 14 publications

References 53 publications

Atezolizumab Plus Bevacizumab Versus Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis

Atezolizumab Plus Bevacizumab Versus Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis

Impact of combining Lenvatinib with Transarterial chemoembolization for unresectable hepatocellular carcinoma

Managing the Adverse Events Associated with Pembrolizumab and Lenvatinib Therapy in Endometrial Cancer

Contact Info

Product

Resources

About